The 3rd Annual Drug Discovery Chemistry Europe 2026 will bring together medicinal chemists, drug discovery scientists and industry experts to discuss advances in small-molecule drug discovery, medicinal chemistry strategies and approaches to identifying and optimising potential drug candidates.
TCG Lifesciences will be part of these conversations, bringing expertise across medicinal chemistry, custom synthesis, library synthesis, PROTAC and molecular-glue chemistry, peptide chemistry, and macrocyclic chemistry. Its integrated discovery capabilities also span analytical chemistry, in vitro pharmacology, DMPK and in vivo pharmacology, supporting research programmes from early discovery through lead optimisation and beyond.
Attendee: Sarah Chatterjee, Associate Vice President – Business Development
